Balyasny Asset Management L.P. Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Balyasny Asset Management L.P. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 56.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 165,973 shares of the biotechnology company's stock after selling 218,359 shares during the period. Balyasny Asset Management L.P. owned about 0.17% of Sarepta Therapeutics worth $20,181,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Manchester Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares during the period. Newbridge Financial Services Group Inc. bought a new position in Sarepta Therapeutics during the 4th quarter worth approximately $36,000. Steward Partners Investment Advisory LLC lifted its position in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 216 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC lowered their target price on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating for the company in a research note on Wednesday. Evercore ISI downgraded Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective on the stock. in a research note on Thursday. Royal Bank of Canada decreased their target price on Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a research note on Wednesday. Piper Sandler dropped their price target on Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday. Finally, Scotiabank dropped their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research note on Thursday, March 20th. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $131.22.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 7.70% of the company's stock.

Sarepta Therapeutics Price Performance

Shares of SRPT traded down $0.25 during trading hours on Friday, reaching $36.27. 6,614,378 shares of the company's stock traded hands, compared to its average volume of 1,621,069. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm's 50 day simple moving average is $66.84 and its 200-day simple moving average is $100.66. The stock has a market cap of $3.56 billion, a PE ratio of 29.02 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 12 month low of $35.46 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The company had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same period in the previous year, the company earned $0.73 EPS. Sarepta Therapeutics's quarterly revenue was up 80.2% on a year-over-year basis. Equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.